Mallinckrodt beats Q2 earnings, misses on revenue

Shares in Mallinckrodt Pharmaceuticals (NYSE:MNK) fell today after the company beat earnings estimates but missed on revenue with its second quarter results.

The U.K.-based company posted profits of $62.8 million, or 72¢ per share, on sales of $824.5 million for the 3 months ended June 30, for bottom-line loss of -68% on sales loss of -5% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Mallinckrodt beats Q2 earnings, misses on revenue appeared first on MassDevice.

from MassDevice http://ift.tt/2fq1pkM